While elevated nuclear ATF2 levels have been reported in AD46,47, Parkinson’s disease models48 and stroke49, little is known about the mechanisms driving its translocation to the nucleus or its downstream targets in neurons. This evidence concerns the gene ATF2 and Parkinson disease.